Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1034750 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR26636359_1.fastq.gz | Fastqsanger.gz | |||
| SRR26636359_2.fastq.gz | Fastqsanger.gz | |||
| SRR26636360_1.fastq.gz | Fastqsanger.gz | |||
| SRR26636360_2.fastq.gz | Fastqsanger.gz | |||
| SRR26636361_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 72 |
Similar Datasets
Project description:Spanning August 2020 to July 2022, this model reconstructs SARS-CoV-2 infection and reinfection dynamics across multiple variants — mainly wildtype, Alpha, Delta, and Omicron BA.4/5. It describes how each variant spread through the population, incorporating cross-immunity between variants. The model is calibrated using seroprevalence data, PCR positivity rates, and variant sequencing, providing insights into how prior infections shaped susceptibility to future waves.
2025-04-12 | MODEL2504120001 | BioModels
Project description:Previously, we introduced an absolute and physical quantitative scale for chromatin immunoprecipitation followed by sequencing. The scale itself was detemined directly from measurements routinely made on sequencing samples without additional reagents or spike-ins. We called this approach sans spike-in quantitative ChIP, or siQ-ChIP. In this paper we extend those results in several ways. First, we simplified the calculations defining the quantitative scale. Second, we highlight the normalization constraint implied by the quantitative scale and introduce a new scheme for generating 'tracks' for siQ-ChIP. We next introduce some whole-genome analyses that are unique to siQ-ChIP which allow us, for example, to project the IP mass onto the genome to evaluate how much of any genomic interval was captured in the IP. We apply these analyses to p300/CBP inhibition and demonstrate that response to inhibition is a function of genomic architecture. In particular, active transcription start sites are only weakly perturbed by p300/CBP inhibition while enhancers are strongly perturbed. Similar observations have been reported in the literature, but without a quantitative scale, those observations have been misinterpreted. We discuss how the siQ-ChIP approach precludes such misinterpretations, which stem from the wide spread community practice of treating unquantified and unnormalized ChIP-seq tracks as though they are quantitative.
2022-07-11 | GSE207783 | GEO
Project description:We previously developed sans spike-in quantitative chromatin immunoprecipitation sequencing (siQ-ChIP), a technique that introduces an absolute quantitative scale to ChIP-seq data. The absolute scale is possible because the IP step of ChIP is a competitive binding reaction and produces a classical binding isotherm when antibody or epitope is titrated. The mathematical model that led to siQ-ChIP also predicts that sequencing samples from along an isotherm can reveal differential preferences of the antibody for specific chromatin regions, if the antibody binds with different strengths to different regions. In this paper, we directly test this prediction with several histone post-translational modification (PTM) antibodies. When titrating these antibodies, we identified on- and off-target interactions directly in ChIP-seq. Antibodies that displayed mostly on-target interactions had small, uniform responses for different regions of chromatin, while antibodies that contained off-target interactions had large, variable responses, indicating differences in binding affinity for different chromatin regions. The generation of an isotherm is essential to perform siQ-ChIP analysis. Therefore, we also present a detailed and simplified wet lab protocol, optimized to reproducibly achieve a binding isotherm. We highlight several benchmarks of success that can be used to gain confidence in ChIP experiments, serving as a guide for the practice of siQ-ChIP. Collectively, these studies demonstrate an optimized siQ-ChIP protocol that can be used to determine histone PTM antibody specificity directly in sample chromatin without any exogenous spike-in reagents and at minimal sequencing depth.
2022-09-03 | GSE212386 | GEO
Project description:Recently, next-generation sequencing has been introduced as a promising, new platform for assessing the copy number of transcripts, while the existing microarray technology is considered less reliable for absolute, quantitative expression measurements. Nonetheless, so far, results from the two technologies have only been compared based on biological data, leading to the conclusion that, although they are somewhat correlated, expression values differ significantly. Here, we use synthetic RNA samples, resembling human microRNA samples, to find that microarray expression measures actually correlate better with sample RNA content than expression measures obtained from sequencing data. In addition, microarrays appear highly sensitive and perform equivalently to next-generation sequencing in terms of reproducibility and relative ratio quantification.
2009-09-08 | GSE14511 | GEO
Project description:The RNA-seq data provided here were collected in order to examine the effect of identified coding and non-coding genomic aberrations on gene expression, as part of the publication ‘Whole-genome sequencing of chronic lymphocytic leukemia (CLL) identifies subgroups with distinct biological and clinical features’ by Robbe et al, Nat Gen, 2022.
2022-10-31 | E-MTAB-12124 | biostudies-arrayexpress
Project description:We performed deep targeted somatic mutation analysis to identify cases of clonal hematopoiesis (CH) associated with pre-leukemic mutations. For the healthy cohort, we used our CH panel V3, containing 705 probes, covering leukemia-related Single Nucleotide Variants (SNVs) and Indels in 47 genes, complemented by two amplicon sequencing reactions to cover GC-rich regions in SRSF2 and ASXL1. For the cytopenic cohort, we used our CH panel V4 (described in detail in Biezuner, T. et al., NAR Genom Bioinform, 2022). Both panels were designed to ensure capture uniformity and specificity. Each DNA sample was sequenced twice with a minimum depth of 1,000,000 paired-end reads on an Illumina Novaseq 6000 machine.
2025-01-08 | E-MTAB-14777 | biostudies-arrayexpress
Project description:The World Health Organization Classification of Hematolymphoid Tumors (WHO) and the International Consensus Classification (ICC) of 2022 introduced major changes to the definition of CMML. To assess qualitative and quantitative implications for patient care, we started with 3,311 established CMML cases (according to WHO 2017 criteria) and included also 2,130 oligomonocytosis cases fulfilling the new CMML diagnostic criteria. Applying both classification systems from 2022, 356 and 241 of oligomonocytosis cases were newly classified as myelodysplastic (MD)-CMML (WHO and ICC 2022, respectively), most of which were diagnosed as MDS according to WHO 2017. Importantly, 1.5 times more oligomonocytosis cases were classified as CMML according to WHO 2022 than based on ICC, due to different diagnostic criteria. Genetic analyses of the newly classified CMML cases showed a distinct mutational profile with strong enrichment of MDS-typical alterations, resulting in a transcriptional subgroup separated from established MD- and myeloproliferative (MP)-CMML. Despite a different cytogenetic, molecular, immunophenotypic, and transcriptional landscape, no differences in overall survival were found between newly classified and established MD-CMML cases. To the best of our knowledge, this study represents the most comprehensive analysis of routine CMML cases to date, both in terms of clinical characterization and transcriptomic analysis, placing newly classified CMML cases on a disease continuum between MDS and previously established CMML.
2023-12-07 | GSE249547 | GEO
Project description:Acute myeloid leukemia (AML) and DNMT3A mutations (DNMT3Amut) are considered to carry intermediate risk under the 2022 European LeukemiaNet (ELN-2022) classification in the absence of other co-mutations or cytogenetic abnormalities. However, this group is highly heterogeneous. In this study, the genomic and transcriptomic features influencing outcomes in DNMT3A-mutated AML were examined in a cohort of 884 patients with AML receiving standard chemotherapy. Stratification by NPM1 and FLT3-ITD status revealed worse survival among patients with NPM1 mutations and wild-type FLT3-ITD (NPM1mut/FLT3-ITDwt) than patients in the ELN-2022 favorable risk group. The other three subgroups (NPM1mut/FLT3-ITDmut, NPM1wt/FLT3-ITDmut, and NPM1wt/FLT3-ITDwt) exhibited worse prognoses than patients in the ELN-2022 intermediate risk group. Additionally, the presence of TET2mut in patients with AML and DNMT3Amut/NPM1mut/FLT3-ITDwt led to reclassification from favorable risk to intermediate risk in the ELN-2022. RNA-sequencing analysis revealed a distinct transcriptomic profile in patients with TET2mut, highlighting the enrichment of leukemic stem cell signatures and dendritic cell migration, with MMP14, CD200, and CT45A5 identified as key differentially expressed genes. In conclusion, co-mutation patterns strongly affected AML outcomes in patients with DNMT3Amut. Patients with TET2mut constituted a unique subgroup within the ELN-2022 favorable DNMT3Amut/NPM1mut/FLT3-ITDwt group, characterized by distinct transcriptomic features and an unfavorable prognosis.
2025-05-19 | GSE297413 | GEO
Project description:We use Saccharomyces cerevisiae to perform absolute quantitative multi-omics analysis to map interactions of different cellular processes during the yeast cell cycle.
2020-03-30 | E-MTAB-8565 | biostudies-arrayexpress
Project description:Interventions: An explorative prospective multicenter cohort study in the Maastricht University Medical Centre+, Catharina Hospital and Zuyderland Medical Centre will be performed in 66 patients. Before, during, and after three cycles of systemic treatment with capecitabine or TAS-102, fecal samples and questionnaires (concerning compliance and chemotoxicity) will be collected. The response will be measured by CT/MRI using RECIST-criteria. Fecal microbiota composition will be analyzed with 16S rRNA next-generation sequencing. The absolute bacterial abundance will be assessed with quantitative polymerase chain reaction. Multivariate analysis will be used for statistical analysis.
Primary outcome(s): Microbiota composition before, during and after 3 cycles systemic treatment with capecitabine or TAS-102 related to respons & chemotoxicity
Study Design: N/A , unknown, Other
| 20955 | ecrin-mdr-crc